Top 10 Deals of 2022: Overview

Amboy Street Ventures’ Top 10 Deals of 2022 series looks at this year’s four major M&A trends in the women’s health and sexual health space.

What are the potential exit paths for women’s health and sexual health companies?

As we kick-off our second annual “Top 10 Deals of the Year” series, we dive into the key exit trends of 2022 in the women’s health and sexual health space.

While the ten year bull market came to a close and IPOs and SPACs seemed to have disappeared, the women’s health and sexual health category still boasted strong exits in 2022 – all thanks to mergers & acquisitions! The massive exits this year further support the recession-resistant nature of the women’s health and sexual health market.

Our 2022 top 10 deals can be categorized into four major M&A trends:

1) Consumer packaged goods (CPG) conglomerates acquired women’s health and sexual health companies to fill gaps in their brand portfolios (blog here),

2) Late stage venture backed companies grew through strategic acquisitions (blog here),

3) Mature healthcare companies decided to buy instead of build in order to innovate (blog here), and

4) PE funds dipped their toes in women’s health and sexual health acquisitions (blog here).

Stay tuned over the next few weeks as Amboy Street reveals the women’s health and sexual health top 10 deals of 2022 within these four M&A trends.

Finally, as it is election day – the future of women’s reproductive rights is in our hands. We hope to see you at the polls!

Continue Reading

Top 10 Deals of 2024: Hologic Acquires Endomag for $310M

This week we highlight a second acquisition by the active women’s health acquirer, Hologic, in a large market segment of women’s health: breast cancer.

Top 10 Deals of 2024: IVI RMA Acquires Eugin Group for $535M

This week we explore one of a growing number of consolidation plays in the IVF space, IVI RMA’s acquisition of Boston IVF and TRIO. This trend suggests there is value in 4-wall IVF clinics, reflecting an interesting area of investment.

Top 10 Deals of 2024: Hologic Acquires Uterine Fibroid Treatment Company for $350M

This blog assesses a recent women’s health deal that expands treatment options for uterine fibroids and abnormal uterine bleeding. These indications are infrequently discussed and therefore unfamiliar to many, yet impact a significant number of women, especially those in perimenopause.

Top 10 Deals of 2024: Hologic Acquires Endomag for $310M

This week we highlight a second acquisition by the active women’s health acquirer, Hologic, in a large market segment of women’s health: breast cancer.

Top 10 Deals of 2024: IVI RMA Acquires Eugin Group for $535M

This week we explore one of a growing number of consolidation plays in the IVF space, IVI RMA’s acquisition of Boston IVF and TRIO. This trend suggests there is value in 4-wall IVF clinics, reflecting an interesting area of investment.

Fast track our industry.
Get in touch today.